Optimised platform for the personalised production of transgenic TCR in T lymphocytes

TCR-READY aims at establishing optimized methods for the identification of tumour-specific T Cell Receptors (TCR) to be transduced as transgenic TCRs into T lymphocytes to contribute to the development of a personalised advanced therapy to treat Chronic Lymphocytic Leukaemia (CLL). TCR-READY will tackle the main challenges for TCR personalized therapies application to patients by developing methods for identification and generation of tumour-specific transgenic TCR in reduced timing; and optimizing the production process of viral vectors used to manufacture such personalised therapy following Good Manufacturing Practices (GMP) standards.